| Symbol
| TFPI
| contributors: mct/ - updated : 22-10-2017
|
| HGNC name
| tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor)
|
| HGNC id
| 11760
|
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
| --other
|
|
weaker expression in cancer cells localised in lymph node metastatic foci of breast cancer  | | constitutional
|
|
| --low
|
| |
in genetic and acquired protein S deficiency and concomitant TFPI deficiency substantially contributes to the hypercoagulable state associated with protein S deficiency | | constitutional
|
|
| --over
|
| |
in pregnant patients at 20 weeks gestation who subsequently develop preeclampsia | | constitutional
|
|
|
| gain of function
| |
in acute skin wounds as well as wound edges of chronic leg ulcers | |
| Susceptibility
|
putative susceptibility gene for venous thrombosis (536GC->T) risk of restenosis after coronary angioplasty to venous thromboembolism |
| Variant & Polymorphism
other
| low levels of free TFPI are at an increased risk of recurrent venous thromboembolism |
|
minus 33C allele has been reported to be associated with elevated total TFPI plasma levels compared to the minus 33T and has thus been suggested to be associated with a lowered risk of venous thrombosis |
| 
|
Candidate gene
Marker
Therapy target
|
|
| System | Type | Disorder | Pubmed |
|---|
| blood | coagulation | | |
| inhibition of TFPI might be a promising novel treatment approach, especially in haemophilia patients with FVIII inhibitors |
| | | |